UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042893
Receipt number R000048962
Scientific Title prognostic analysis of non-small cell lung cancer patients with pathological stage II-IIIB
Date of disclosure of the study information 2021/01/05
Last modified on 2024/01/07 10:10:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

prognostic analysis of non-small cell lung cancer patients with pathological stage II-IIIB

Acronym

prognostic analysis of non-small cell lung cancer patients with pathological stage II-IIIB

Scientific Title

prognostic analysis of non-small cell lung cancer patients with pathological stage II-IIIB

Scientific Title:Acronym

prognostic analysis of non-small cell lung cancer patients with pathological stage II-IIIB

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Pneumology Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine the prognostic value of cisplatin unfit in postoperative lung cancer patients with stage II-III pathology requiring cisplatin-based adjuvant chemotherapy

Basic objectives2

Others

Basic objectives -Others

Reasons why standard postoperative adjuvant chemotherapy could not be administered and alternative treatments

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Overall survival by postoperative adjuvant therapy

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

patients who underwent surgery for non-small cell lung cancer between 2010 and 2020, patients with pathological stage II-IIIB requiring postoperative adjuvant chemotherapy as standard treatment will be included.

Key exclusion criteria

Non-complete resection cases

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Toyofumi Fengshi
Middle name
Last name Chen-Yoshikawa

Organization

Nagoya University

Division name

Graduate School of Medicine, Department of Thoracic Surgery

Zip code

4668550

Address

65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, JAPAN

TEL

0527442375

Email

tyoshikawa@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name Shota
Middle name
Last name Nakamura

Organization

Nagoya University

Division name

Graduate School of Medicine, Department of Thoracic Surgery

Zip code

4668550

Address

65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, JAPAN

TEL

0527442375

Homepage URL


Email

shota197065@med.nagoya-u.ac.jp


Sponsor or person

Institute

Nagoya University

Institute

Department

Personal name



Funding Source

Organization

Nagoya University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya university hospital

Address

65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

Tel

0527442375

Email

shota197065@med.nagoya-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 05 Day


Related information

URL releasing protocol

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://nagoya.bvits.com/rinri/publish_document.

Publication of results

Unpublished


Result

URL related to results and publications

none

Number of participants that the trial has enrolled

1400

Results

none

Results date posted

2024 Year 01 Month 07 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

CDDP unfit patients

Participant flow

retrospective study

Adverse events

none

Outcome measures

none

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 02 Month 01 Day

Date of IRB


Anticipated trial start date

2021 Year 02 Month 01 Day

Last follow-up date

2022 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

retrospective observational study


Management information

Registered date

2021 Year 01 Month 04 Day

Last modified on

2024 Year 01 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048962